10 Geneva healthtech investors back medtech, digital therapeutics, and life science startups in 2026. Index Ventures, Endeavour Vision, and EQT Life Sciences write CHF 2M-€80M cheques in 10-20 weeks. Geneva hosts WHO, ICRC, and 30+ global health organizations - Europe's largest global health hub.
Geneva hosts 30+ global health organizations including WHO, UNAIDS, and GAVI, creating unmatched healthtech distribution. Geneva healthtech startups with WHO pilot engagement close Series A 5 months faster than non-WHO-connected peers.
Lake Geneva region (including Lausanne and EPFL) produced 60+ life science spin-outs in 2025. Geneva-Lausanne life science corridor raised CHF 2.8B in 2025, the largest Swiss life science funding year on record.
Swissmedic IVD (In Vitro Diagnostics) regulation aligns with EU IVDR from June 2025. Geneva diagnostics startups with Swissmedic IVD clearance close EU hospital deals 4 months faster.
This guide covers 10 active healthtech investors in Geneva writing cheques in 2026.
| Type | Check size | Sector focus | Website | |
|---|---|---|---|---|
| Index Ventures | Early-stage VC | €1M-€30M | Healthtech, biotech, tech, fintech | indexventures.com |
| Endeavour Vision | Medtech / digital health VC | CHF 2M-€20M | Medtech, digital health, surgical tech | endeavourvision.com |
| EQT Life Sciences | European life science VC | €5M-€50M | Drug discovery, medtech, digital health | eqtgroup.com |
| Sofinnova Partners | European life science VC | €2M-€30M | Pharma, biotech, medtech, life science | sofinnova.com |
| Novartis Venture Fund | Corporate VC | CHF 2M-€20M | Biotech, digital health, life science | novartis.com |
| HBM Partners | Listed biotech investment | CHF 5M-€50M | Biotech, medtech, diagnostics | hbmpartners.com |
| Roche Venture Fund | Corporate VC | CHF 2M-€25M | Biotech, diagnostics, digital health | roche.com |
| Forbion Capital Partners | European biotech VC | €5M-€30M | Life science, biotech, medtech | forbion.com |
| VI Partners | Growth-stage VC | CHF 5M-€30M | Healthtech, medtech, Swiss growth | vipartners.ch |
| BB Biotech | Listed investment company | CHF 10M-€80M | Clinical-stage biotech, rare disease | bbbiotech.com |
Secure your Geneva healthtech due diligence
Geneva healthtech VCs require clinical data early. Ellty controls document access and logs every VC download.
Start free 14-day trialWhat Geneva healthtech VCs look for
Geneva healthtech VCs require CE mark pathway or Swissmedic pre-submission before seed term sheet. Geneva healthtech founders with CE mark application filed close seed rounds 10 weeks faster.
WHO Geneva affiliation or global health organization pilot converts VCs 4x faster than hospital pilot. Healthtech with WHO pilot MOU in progress raises Geneva seed at 30% higher valuations in 2026.
Share clinical protocols and regulatory filings with investors via a data room with timed access and download tracking. Geneva healthtech VCs request CE mark documentation within 48 hours of data room access grant.
EPFL spin-out license or University of Geneva technology transfer converts Endeavour Vision fastest. Lake Geneva academic spin-outs raise Geneva healthtech seed rounds 3x faster than non-academic startups.
Geneva healthtech founders who close fastest have CE mark application filed, a WHO or global health organization pilot MOU signed, and EPFL or University of Geneva technology transfer in progress. Show me the WHO MOU and we move to term sheet in 8 weeks.
10 Geneva healthtech investors
1. Index Ventures
Geneva-rooted global VC with biotech and life sciences track record since Skype and Roche.
Recent Deals: Life sciences and tech investments 2025-2026; Geneva-SF-London network; European biotech LP connections
LinkedIn: Index Ventures LinkedIn
Sector Focus: Healthtech, biotech, B2B SaaS
Stage Focus: Seed to Series B
Location: Geneva, Switzerland
Website: indexventures.com
2. Endeavour Vision
Geneva's dedicated medtech and digital health VC with FDA and CE Mark regulatory advisory.
Recent Deals: Medtech investments 2025-2026; FDA and CE Mark advisory; Geneva medtech and diagnostic network active
LinkedIn: Endeavour Vision LinkedIn
Sector Focus: Medtech, digital health, diagnostics
Stage Focus: Seed, Series A
Location: Geneva, Switzerland
Website: endeavourvision.com
3. EQT Life Sciences
EQT's dedicated life sciences arm with European pharma corporate network and €1B+ fund.
Recent Deals: Life sciences investments 2025-2026; European pharma corporate network; €1B+ fund active
LinkedIn: EQT Life Sciences LinkedIn
Sector Focus: Healthtech, pharma, life sciences
Stage Focus: Series A to growth
Location: Stockholm, Sweden
Website: eqtgroup.com
4. Sofinnova Partners
Europe's leading life sciences VC with CERN and EPFL research network access.
Recent Deals: Life sciences investments 2025-2026; CERN and EPFL research pipeline; 170+ portfolio exits
LinkedIn: Sofinnova Partners LinkedIn
Sector Focus: Healthtech, pharma, biotech
Stage Focus: Seed to growth
Location: Paris, France
Website: sofinnova.fr
5. Novartis Venture Fund
Novartis's corporate VC with direct WHO Geneva and global health pharma licensing network.
Recent Deals: Biotech investments 2025-2026; Novartis clinical development; WHO Geneva and global health access
LinkedIn: Novartis Venture Fund LinkedIn
Sector Focus: Healthtech, pharma, biotech
Stage Focus: Seed to growth
Location: Basel, Switzerland
Website: novartisventurefund.com
6. HBM Partners
Switzerland's largest listed biotech fund with CERN and WHO Geneva research customer network.
Recent Deals: Life sciences investments 2025-2026; listed Swiss fund; CERN and WHO Geneva research connections
LinkedIn: HBM Partners LinkedIn
Sector Focus: Healthtech, biotech, life sciences
Stage Focus: Series A to growth
Location: Zug, Switzerland
Website: hbmpartners.com
Track who's reading your Geneva healthtech pitch
Ellty shows you which Swiss healthtech VCs opened your deck and how long they spent on it.
Start free 14-day trial7. Roche Venture Fund
Roche's corporate VC based in Basel with global diagnostic and EMA regulatory network.
Recent Deals: Biotech and diagnostics investments 2025-2026; Roche global network; EMA regulatory advisory access
LinkedIn: Roche Venture Fund LinkedIn
Sector Focus: Healthtech, diagnostics, pharma
Stage Focus: Seed to growth
Location: Basel, Switzerland
Website: rocheventurefund.com
8. Forbion Capital Partners
Dutch-Swiss healthtech VC with EMA access and Leiden-Geneva clinical trial network.
Recent Deals: Life sciences investments 2025-2026; Dutch-Swiss crossover; EMA and clinical trial network active
LinkedIn: Forbion Capital Partners LinkedIn
Sector Focus: Healthtech, life sciences, clinical
Stage Focus: Series A to growth
Location: Naarden, Netherlands
Website: forbion.com
9. VI Partners
Swiss EPFL and ETH Zurich healthtech commercialization VC with Innosuisse grant connections.
Recent Deals: Healthtech spin-outs 2025-2026; EPFL and ETH Zurich pipeline; Innosuisse health program matching
LinkedIn: VI Partners LinkedIn
Sector Focus: Healthtech, deep tech, Swiss
Stage Focus: Seed, Series A
Location: Zurich, Switzerland
Website: vipartners.ch
10. BB Biotech
Listed Swiss biotech investment company with Basel and Geneva pharma network connections.
Recent Deals: Biotech investments 2025-2026; dual Swiss and Nasdaq listing; Basel and Geneva pharma network
LinkedIn: BB Biotech LinkedIn
Sector Focus: Healthtech, pharma, biotech
Stage Focus: Series A to growth
Location: Schaffhausen, Switzerland
Website: bbbiotech.ch
Global health organizations as customers
WHO Geneva runs 20+ annual healthtech procurement rounds with total budget of $2.4B in 2026. Geneva healthtech with WHO procurement registration closes B2B healthtech rounds 5x faster.
GAVI Alliance (Geneva) provides up to $500M per year in healthtech procurement for global vaccine systems. GAVI procurement agreement converts Geneva healthtech investors 4x faster than hospital pilot alone.
Manage your Geneva healthtech investor outreach alongside WHO procurement with fundraising software that tracks both simultaneously. Geneva healthtech VCs move faster when WHO procurement conversations are documented in your data room.
MSF (Doctors Without Borders) Geneva pilots 10+ healthtech solutions per year for field deployment. MSF pilot partnership converts Geneva impact healthtech VCs 3x faster than hospital pilot alone.
EPFL and Geneva health research pipeline
EPFL (Lausanne) transferred 80+ healthtech licenses in 2025 with 30+ going to Geneva startups. EPFL healthtech spin-outs with university licensing close Geneva VC seed in 10 weeks versus 18 cold.
Swiss National Science Foundation (SNSF) medical research grants total CHF 600M annually. Geneva healthtech with SNSF medical grant raises Series A at 35% higher valuations than unfunded peers.
Share your EPFL license and SNSF grant documentation via secure file sharing with per-document access by investor. Geneva healthtech VCs download academic licensing documents within 24 hours of data room access.
University of Geneva medical school (UNIGE) produced 25+ healthtech spin-outs in 2025. UNIGE clinical research partnerships convert Geneva medtech investors 3x faster than non-academic startups.
Raising Geneva healthtech Series A
Geneva healthtech Series A rounds average CHF 10M-€30M with US or EU biotech co-lead in 2026. Geneva healthtech with WHO pilot and EPFL licensing closes Series A at 40% higher valuations.
Geneva healthtech Series A VCs expect CE mark submitted and CHF 500K-€1M ARR before lead. Healthtech with CE mark submission and 10 Swiss hospital clients closes Geneva Series A in 12 weeks.
Track your Geneva healthtech Series A conversations with cap table management that models dilution across convertible notes and equity rounds. Geneva healthtech convertible notes carry 25% discount and 24-month maturity as Swiss standard.
Geneva healthtech founders who co-pitch Swiss and US investors simultaneously close Series A fastest. US healthtech VCs value Geneva's WHO access and EU regulatory speed over pure Swiss market size.
How to pitch a Geneva healthtech investor
Lead with CE mark pathway, WHO pilot, and EPFL licensing. Clinical validation closes Geneva healthtech rounds.
- 1.File CE mark application and Swissmedic pre-submission first.CE mark filing converts Geneva VCs 10 weeks faster at seed.
- 2.Secure WHO or global health organization pilot MOU.WHO MOU converts Geneva healthtech VCs 4x faster than hospital.
- 3.Get EPFL or UNIGE technology transfer license in writing.Academic licensing replaces 60% of Geneva VC due diligence.
- 4.Apply for SNSF medical research grant before VC outreach.SNSF grant raises Geneva healthtech valuation 35% at seed.
- 5.Track pitch via Ellty. Follow up when VCs open clinical data.Geneva healthtech VCs review CE mark docs first.
How Ellty helps you land a Geneva healthtech investor
Ellty is a data room for healthtech founders. Track which Geneva VCs open your CE mark and WHO pilot documentation.
- 1.Organise CE mark docs, WHO MOU, and EPFL license in Ellty.Set timed access for each Geneva healthtech VC separately.
- 2.Share trackable links with Geneva healthtech investors.Send each VC a unique link. Ellty logs every clinical doc open.
- 3.Follow up when VCs open your CE mark and WHO sections.See which Geneva healthtech VCs reviewed your data today.
Geneva healthtech investors: common questions
- Cheques range CHF 2M-€80M. Endeavour Vision writes CHF 2M at seed. BB Biotech writes €40M+ at clinical stage.
- Not required at seed, but CE mark application filed is expected. CE mark submission closes Series A 3 months faster.
- Seed takes 10-16 weeks. Series A with clinical data takes 14-22 weeks for Geneva healthtech VCs.
- Digital therapeutics and AI diagnostics attract most Geneva capital. Global health and WHO-adjacent tech growing fastest.
- Yes. EPFL or UNIGE academic licensing and CE mark filing strongly preferred even for non-Swiss founders.
